Report cover image

High-Grade Glioma - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 200 Pages
SKU # DEL18679621

Description

High-Grade Glioma - Pipeline Insight, 2024



DelveInsight’s, “High-grade Glioma – Pipeline Insight, 2024,” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in High-grade Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
High-grade Glioma Understanding

High-grade Glioma: Overview

A glioma is a name for tumours of the glial cells. These are the supporting cells of the nervous system. Gliomas can arise in any part of the brain and may also be found in the spinal cord. More than half of all brain tumours in children are gliomas. There are different types of gliomas. Physicians use the terms “glioma” and “astrocytoma” interchangeably.

High grade means that the glioma is growing rapidly. High grade gliomas are either World Health Organization (WHO) grade 3 tumours or grade 4. Grade 3 and 4 tumours tend to grow rapidly and spread faster than tumours of a lower grade.

The most common grade 3 tumour is anaplastic astrocytoma and the most common grade 4 tumour is glioblastoma multiforme. Other more complex high grade gliomas include: oligoastrocytoma, pleiomorphic xanthoastrocytoma, and gliosarcoma.

Symptoms

Children with supratentorial high grade gliomas show signs and symptoms that depend on which area of the brain is involved. There may be neurological deficits, seizures, accompanied by signs and symptoms of increased intracranial pressure:
  • Headaches, mostly in the morning
  • Nausea and vomiting, mostly in the morning
  • Blurred or decreased vision
  • Sluggishness or drowsiness
  • Changes in behaviour
  • Seizures
Diagnosis

Typical imaging techniques such as MRI or CT may be used to determine that there is a tumour present, but the actual diagnosis of a supratentorial high grade glioma depends on histological testing. Histological testing is when a biopsy is done to remove a small sample of the tumour from the brain, and the sample is studied under the microscope for the presence or absence of certain characteristics. Complete staging, using MRI of the spine and examination of the cerebrospinal fluid, is not usually a part of the initial diagnostic testing. However, high grade gliomas can spread, and if there are any concerns, complete staging will be considered.

Treatment

Treatment of high grade gliomas include:
  • Surgery is the main form of treatment and is combined with radiation and chemotherapy in children older than three years old.
  • Chemotherapy has not yet been shown to have a proven benefit in the treatment of this tumour type.
High-grade Glioma Emerging Drugs Chapters

This segment of the High-grade Glioma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

High-grade Glioma Emerging Drugs
  • OT101: Mateon Therapeutics
OT101, a first-in-class RNA therapeutic, is designed to abrogate the immunosuppressive actions of TGF-beta 2. In a completed Phase II clinical study, OT-101 exhibited clinically meaningful single-agent activity and induced durable complete and partial responses in recurrent and refractory adult high-grade glioma patients, including adults with GBM. Further development of OT-101 may offer renewed hope for salvage therapy of pediatric DIPG patients who have this rare and fatal disease.
  • BMX-001: BioMimetix
BMX-001 is being studied in a phase II randomized trial studying the safety and efficacy of the investigational drug in patients with newly diagnosed high-grade glioma patients who are being treated with brain radiation and temozolomide. The concluded Phase I study provided the following:
  • A clean safety profile
  • Clear evidence for bone marrow protection
  • Early indications for protection of cognitive function
  • Survival data consistent with a positive trend
  • The dose and regimen for Ph2 and clinical practice
  • OKN-007: Oblato, Inc.
OKN-007 is being developed by Oblato, Inc for the treatment of High-grade Glioma. It is currently in phase I/II stage of development.
  • PTC596: PTC Therapeutics
PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. PTC596 acts by altering and destroying the BMI1 protein through a process called phosphorylation. PTC596 has potently inhibited BMI1 function in multiple tumor cell lines. In in vitro tests, PTC596 has preferentially targeted chemotherapy resistant cancer stem cells. Specifically, PTC596 preferentially depleted cancer stem cells in assays with tumor cell lines from fibrosarcoma, prostate and colon cancers. Conversely, the cytotoxic chemotherapies carboplatin, temozolomide, methotrexate and indibulin enriched the population of cancer stem cells in this assay. It is currently in phase I stage of development.

Further product details are provided in the report……..

High-grade Glioma: Therapeutic Assessment

This segment of the report provides insights about the different High-grade Glioma drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in High-grade Glioma
There are approx. 150+ key companies which are developing the therapies for High-grade Glioma. The companies which have their High-grade Glioma drug candidates in the most advanced stage, i.e. phase III include Mateon Therapeutics and others
  • Phases
DelveInsight’s report covers around 150+ products under different phases of clinical development like
  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage products (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
High-grade Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravenous
  • Oral
  • Parenteral
  • Subcutaneous
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Gene therapies
  • Small molecule
  • Vaccines
  • Polymers
  • Peptides
  • Monoclonal antibodies
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

High-grade Glioma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses High-grade Glioma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging High-grade Glioma drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence High-grade Glioma R&D. The therapies under development are focused on novel approaches to treat/improve High-grade Glioma.
  • In October 2018, Oblato acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of glioblastoma, a deadly form of brain cancer.
  • In September 2019, Mateon Therapeutics announced that the US Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation for OT101/Trabedersen for the treatment of diffuse intrinsic pontine glioma (DIPG) as a drug for a “rare pediatric disease.”
High-grade Glioma Report Insights
  • High-grade Glioma Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
High-grade Glioma Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing High-grade Glioma drugs?
  • How many High-grade Glioma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of High-grade Glioma?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the High-grade Glioma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for High-grade Glioma and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Mateon Therapeutics
  • BioMimetix
  • Oblato, Inc
  • PTC Therapeutics
  • Lee's Pharmaceutical Limited
  • Nuvation Bio, Inc.
  • Laminar Pharmaceuticals
  • Basilea Pharmaceutica
  • Aadi, LLC
  • Erimos Pharmaceuticals
Key Products
  • OT101
  • BMX-001
  • OKN-007
  • PTC596
  • TG02
  • NUV-422
  • 2-OHOA
  • BAL101553
  • ABI-009
  • Terameprocol

Table of Contents

200 Pages
Introduction
Executive Summary
High-grade Glioma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
High-grade Glioma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
High-grade Glioma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
High-grade Glioma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
OT101: Mateon Therapeutics
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II and Phase I/II)
Comparative Analysis
BMX-001: BioMimetix
Product Description
Research and Development
Product Development Activities
OKN-007: Oblato, Inc.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
PTC596: PTC Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
High-grade Glioma Key Companies
High-grade Glioma Key Products
High-grade Glioma- Unmet Needs
High-grade Glioma- Market Drivers and Barriers
High-grade Glioma- Future Perspectives and Conclusion
High-grade Glioma Analyst Views
High-grade Glioma Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us